First-in-human evaluation of [18F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-617
Jiawei He, Yinzhao Wang, Wei Tang, Xiaomei Gao, Yi Cai, Yongxiang Tang, Shuo Hu · 2026
Read First-in-human evaluation of [18F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-617 by Jiawei He, Yinzhao Wang, Wei Tang, Xiaomei Gao, Yi Cai, Yongxiang Tang, Shuo Hu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13276814.txt.
Description
Jiawei He leads a 2026 first-in-human test of a new scan tracer for prostate cancer. The tracer targets a receptor called NTSR1, while the standard tracer targets PSMA, a protein common on prostate cancer cells. Twenty-three men at Xiangya Hospital had both scans before surgery to remove the prostate.
In men who had no hormone treatment yet, the standard tracer found more cancer and missed less. After short hormone treatment, the pattern flipped and the new tracer found more lesions. Tissue tests matched that shift, as one target fell and the other rose. The authors suggest using each tracer at the stage where it works best.
Catalog record
| CREATOR | Jiawei He, Yinzhao Wang, Wei Tang, Xiaomei Gao, Yi Cai, Yongxiang Tang, Shuo Hu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30447 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |